Mazal Plant Pharmaceuticals has also received approval to conduct a large-scale, double-blind, four-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be given either MAHDL, placebo, statin + placebo or MAHDL + statin for four months and tested for changes in HDL, LDL, cholesterol, triglycerides and CRP serum levels.
Eliyahu Tolchinsky, Mazal’s CEO, said: “Building the company’s intellectual portfolio is an important part of building Mazal Plant Pharmaceuticals in tandem with pending clinical trials.”